novo nordisk eli lilly

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk and Zepbound

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

· 2d · on MSN

· 1d

Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

· 2d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

· 2d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Novo Nordisk Inks A Major Obesity Deal

Digest more

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Fierce Biotech · 4h

· 3h · on MSN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

STAT · 4h

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk: A Strategy With High Potential For Volatile Times

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

pharmaphorum1d

Novo Nordisk builds case for Norditropin successor

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as effective as a daily shot of Norditropin (somatropin) in children born small for gestational age (SGA), Noonan syndrome (NS), or with idiopathic short stature (ISS).

6don MSN

Down Nearly 20%: Should You Buy the Dip on Eli Lilly?

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo Nordisk's share is decreasing.